原发性扁桃体淋巴瘤治疗结果分析
Analysis of treatment outcomes for primary tonsillar lymphoma.
作者信息
Lee Yun Hee, Cho Seok Goo, Jung Seung Eun, Kim Sung Hoon, O Joo Hyun, Park Gyeong Sin, Yang Suk Woo, Lee In Seok, Rhee Chin Kook, Choi Byung Ock
机构信息
Department of Radiation Oncology, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
Department of Hematology, Catholic University Lymphoma Group (CULG), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
Radiat Oncol J. 2016 Dec;34(4):273-279. doi: 10.3857/roj.2016.01781. Epub 2016 Oct 31.
PURPOSE
Although each Waldeyer's ring sub-site is considered an independent prognostic factor, few studies have assessed the prognosis and treatment of tonsillar lymphoma. Treatment outcomes were analyzed in patients with primary tonsillar lymphoma who were treated with chemotherapy and radiotherapy (RT).
MATERIALS AND METHODS
Nineteen patients with diffuse large B-cell lymphoma were evaluated, with a median follow-up of 53 months. Age, sex, and histology, amongst other factors, were reviewed. Progression-free survival (PFS) and overall survival (OS) rates were analyzed.
RESULTS
Most patients had Ann Arbor stage I-II (94.7%), IPI score of 0 (89.5%), and complete remission after chemotherapy (89.5%). The 5-year PFS and OS rates were 74.6% and 80%, respectively. In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). RT dose was related to the survival outcome (p = 0.010 for PFS, p = 0.044 for OS). Patients were classified into the CHOP + RT (>40 Gy) group and R-CHOP + RT (≤40 Gy) group. The 5-year PFS rates were 50% in the CHOP + RT group, and 100 % in the R-CHOP + RT group (p = 0.018). The 5-year OS rates were 66.7% and 100%, respectively (p = 0.087).
CONCLUSION
Primary tonsillar lymphoma patients typically have favorable outcomes. Chemotherapy (R-CHOP) combined with relatively lower dose consolidative RT may be safe and effective for primary tonsillar lymphoma.
目的
尽管Waldeyer环的每个亚部位都被视为一个独立的预后因素，但很少有研究评估扁桃体淋巴瘤的预后和治疗。对接受化疗和放疗（RT）的原发性扁桃体淋巴瘤患者的治疗结果进行了分析。
材料与方法
评估了19例弥漫性大B细胞淋巴瘤患者，中位随访时间为53个月。回顾了年龄、性别和组织学等因素。分析了无进展生存期（PFS）和总生存期（OS）率。
结果
大多数患者为Ann Arbor I-II期（94.7%），国际预后指数（IPI）评分为0（89.5%），化疗后完全缓解（89.5%）。5年PFS率和OS率分别为74.6%和80%。单因素分析显示，利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）方案的PFS优于环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）方案（88.9%对50.0%；p = 0.053）。放疗剂量与生存结果相关（PFS为p = 0.010，OS为p = 0.044）。患者被分为CHOP + RT（>40 Gy）组和R-CHOP + RT（≤40 Gy）组。CHOP + RT组的5年PFS率为50%，R-CHOP + RT组为100%（p = 0.018）。5年OS率分别为66.7%和100%（p = 0.087）。
结论
原发性扁桃体淋巴瘤患者通常预后良好。化疗（R-CHOP）联合相对低剂量的巩固性放疗对原发性扁桃体淋巴瘤可能是安全有效的。
Zotero 插件